Thursday 16 October, 2025
Objectives: In pediatric acute lymphoblastic leukemia (ALL), a poor prognosis is observed with refractory disease, early 1st relapse, and ≥…
Read moreAbstracts
Clinical trial design evaluation in pediatric oncology: Phase I dose finding trial design optimization exemplified by brigatinib (ITCC-098)
Thursday 16 October, 2025
Objectives: The primary aim of phase I clinical trials is to define the recommended phase II dose (RP2D) [1]. In…
Read moreThe combined use of propensity score matching and a joint tumor growth dynamics (TGD) – Overall Survival (OS) model to benchmark the efficacy of new treatments for advanced renal cell carcinoma (RCC)
Thursday 16 October, 2025
Objectives: Modeling tumor growth dynamics in different tumor types and under various therapeutic interventions has been an active area of…
Read morePopulation pharmacokinetics of olanzapine and quetiapine in critically ill adults with delirium
Thursday 16 October, 2025
Introduction: The optimal drug and dosage for treating acute delirium lack consensus, especially among critically ill patients whose altered pharmacokinetics…
Read moreAn Exploratory Analysis of the Performance of Methylphenidate Regimens Based on a PKPD Model of Dopamine and Norepinephrine Transporter Occupancy
Thursday 16 October, 2025
Introduction: Methylphenidate (MPH) is a psychostimulant which inhibits the uptake of dopamine and norepinephrine transporters, DAT and NET, and is…
Read moreExternal validation of population pharmacokinetic models on 7 published models of moxifloxacin-treated tuberculosis patients
Thursday 16 October, 2025
Object: Moxifloxacin has a potential role as a first-line agent in fluoroquinolone-based tuberculosis treatment and plays a central role in…
Read morePredicting intrinsic clearance by the integration of deep learning-based drug-metabolic enzyme binding interactions on a canonical in vitro-in vivo extrapolation method
Thursday 16 October, 2025
Introduction: In the clinical field or during the development of small molecule drugs, it is important to predict clearance to optimize…
Read moreUncoupling tumor cell killing and cytokine release following T-cell engager administration with a mechanistic PKPD model
Thursday 16 October, 2025
Objectives: T-cell engagers (TCE) are anti-cancer therapeutic agents that reactivate the patient’s immune system. They are promising therapies with remaining…
Read moreA mechanistic PK/PD model to predict cytokine release and tumor cell killing associated to T-cell bispecific therapies
Thursday 16 October, 2025
Objectives: T-cell bispecifics (TCB) are promising anti-tumor therapies with remaining challenges associated with their clinical safety profiles. In particular, Cytokine…
Read morePopulation Pharmacokinetic Modelling of Norepinephrine in Healthy Volunteers Prior to and During General Anesthesia
Thursday 16 October, 2025
Objectives: Intraoperation hypotension (IOH) is frequently seen in patients undergoing surgery under general anesthesia (GA) and is largely induced by…
Read more